GOALS: Our study reexamines the prevalence of interval colorectal cancer (I-CRC) by manually reviewing CRC cases at a single institution. BACKGROUND: In 2% to 8% of patients with CRC, diagnosis occurs during the interval 6 to 36 months after a cancer-free colonoscopy. Rates are often determined by linking the date of colonoscopy with cancer registry information. STUDY: We examined all colonoscopies from 1993 to 2011. These examinations were linked with Pennsylvania Cancer Registry data. Matched charts were manually reviewed. We determined whether the CRC was "prevalent" or, for patients with a previous colonoscopy, whether they were interval or noninterval based on time from last colonoscopy. For interval cases, we identified "administrative errors" that could falsely increase the number of reported I-CRC. RESULTS: Over the study period, 43,661 colonoscopies were performed, with 1147 (2.6%) positive for CRC after excluding cases (n=52) in which patients had IBD, previous surgery, or nonadenocarcinoma malignancy. Prevalent CRCs totaled 1062 (92.6%). Noninterval CRCs (diagnosed over 36 mo from index colonoscopy) were present in 40 (3.5%). There remained 45 (3.9%) potential I-CRC cases. However, after manual review, 21 cases were found to be administrative errors. Therefore, the accurate proportion of colonoscopies that found an I-CRC was 2.1% (95% confidence interval, 1.5%-3.2%). CONCLUSIONS: The prevalence of I-CRC at our institution before adjustment was comparable with previously reported rates. This proportion was 47% lower after adjusting for administrative errors placing our figure at the lower end of reported I-CRC incidence. Reported rates of I-CRC may be falsely elevated due to errors unique to merging administrative databases.
GOALS: Our study reexamines the prevalence of interval colorectal cancer (I-CRC) by manually reviewing CRC cases at a single institution. BACKGROUND: In 2% to 8% of patients with CRC, diagnosis occurs during the interval 6 to 36 months after a cancer-free colonoscopy. Rates are often determined by linking the date of colonoscopy with cancer registry information. STUDY: We examined all colonoscopies from 1993 to 2011. These examinations were linked with Pennsylvania Cancer Registry data. Matched charts were manually reviewed. We determined whether the CRC was "prevalent" or, for patients with a previous colonoscopy, whether they were interval or noninterval based on time from last colonoscopy. For interval cases, we identified "administrative errors" that could falsely increase the number of reported I-CRC. RESULTS: Over the study period, 43,661 colonoscopies were performed, with 1147 (2.6%) positive for CRC after excluding cases (n=52) in which patients had IBD, previous surgery, or nonadenocarcinoma malignancy. Prevalent CRCs totaled 1062 (92.6%). Noninterval CRCs (diagnosed over 36 mo from index colonoscopy) were present in 40 (3.5%). There remained 45 (3.9%) potential I-CRC cases. However, after manual review, 21 cases were found to be administrative errors. Therefore, the accurate proportion of colonoscopies that found an I-CRC was 2.1% (95% confidence interval, 1.5%-3.2%). CONCLUSIONS: The prevalence of I-CRC at our institution before adjustment was comparable with previously reported rates. This proportion was 47% lower after adjusting for administrative errors placing our figure at the lower end of reported I-CRC incidence. Reported rates of I-CRC may be falsely elevated due to errors unique to merging administrative databases.
Authors: James D Lewis; Kimmie Ng; Kenneth E Hung; Warren B Bilker; Jesse A Berlin; Colleen Brensinger; Anil K Rustgi Journal: Arch Intern Med Date: 2003-02-24
Authors: Douglas J Robertson; E Robert Greenberg; Michael Beach; Robert S Sandler; Dennis Ahnen; Robert W Haile; Carol A Burke; Dale C Snover; Robert S Bresalier; Gail McKeown-Eyssen; Jack S Mandel; John H Bond; Rosalind U Van Stolk; Robert W Summers; Richard Rothstein; Timothy R Church; Bernard F Cole; Tim Byers; Leila Mott; John A Baron Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: Douglas J Robertson; David A Lieberman; Sidney J Winawer; Dennis J Ahnen; John A Baron; Arthur Schatzkin; Amanda J Cross; Ann G Zauber; Timothy R Church; Peter Lance; E Robert Greenberg; María Elena Martínez Journal: Gut Date: 2013-06-21 Impact factor: 23.059
Authors: Ajay Pabby; Robert E Schoen; Joel L Weissfeld; Randall Burt; James W Kikendall; Peter Lance; Moshe Shike; Elaine Lanza; Arthur Schatzkin Journal: Gastrointest Endosc Date: 2005-03 Impact factor: 9.427
Authors: Michael Bretthauer; Lars Aabakken; Evelien Dekker; Michal F Kaminski; Thomas Rösch; Rolf Hultcrantz; Stepan Suchanek; Rodrigo Jover; Ernst J Kuipers; Raf Bisschops; Cristiano Spada; Roland Valori; Dirk Domagk; Colin Rees; Matthew D Rutter Journal: United European Gastroenterol J Date: 2016-02-03 Impact factor: 4.623
Authors: Colin J Rees; Roisin Bevan; Katharina Zimmermann-Fraedrich; Matthew D Rutter; Douglas Rex; Evelien Dekker; Thierry Ponchon; Michael Bretthauer; Jaroslaw Regula; Brian Saunders; Cesare Hassan; Michael J Bourke; Thomas Rösch Journal: Gut Date: 2016-10-08 Impact factor: 23.059